Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update

Anixa Biosciences, Inc. (NASDAQ:ANIXGet Free Report) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 632,100 shares, an increase of 14.3% from the April 15th total of 553,100 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 119,400 shares, the short-interest ratio is currently 5.3 days.

Insider Buying and Selling at Anixa Biosciences

In other news, Director Arnold M. Baskies bought 10,000 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were purchased at an average cost of $3.63 per share, with a total value of $36,300.00. Following the completion of the acquisition, the director now directly owns 110,000 shares in the company, valued at $399,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Arnold M. Baskies acquired 10,000 shares of the stock in a transaction on Friday, March 15th. The shares were purchased at an average cost of $3.63 per share, for a total transaction of $36,300.00. Following the transaction, the director now owns 110,000 shares in the company, valued at approximately $399,300. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Amit Kumar bought 30,000 shares of Anixa Biosciences stock in a transaction dated Friday, March 15th. The stock was acquired at an average price of $3.22 per share, with a total value of $96,600.00. Following the acquisition, the chief executive officer now directly owns 491,925 shares of the company’s stock, valued at $1,583,998.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 55,009 shares of company stock valued at $182,130. Company insiders own 22.60% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its holdings in Anixa Biosciences by 274.6% during the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock valued at $2,110,000 after acquiring an additional 39,820 shares during the period. Simplicity Wealth LLC acquired a new position in shares of Anixa Biosciences during the 1st quarter worth about $44,000. Finally, Staley Capital Advisers Inc. bought a new stake in Anixa Biosciences during the 1st quarter valued at approximately $31,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Stock Down 1.7 %

Shares of ANIX opened at $2.93 on Thursday. The firm has a market cap of $93.47 million, a price-to-earnings ratio of -8.62 and a beta of 0.86. The company’s fifty day moving average is $3.17 and its 200-day moving average is $3.60. Anixa Biosciences has a 12 month low of $2.75 and a 12 month high of $5.13.

Anixa Biosciences (NASDAQ:ANIXGet Free Report) last posted its earnings results on Tuesday, March 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, research analysts predict that Anixa Biosciences will post -0.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Anixa Biosciences in a report on Thursday, March 21st.

Get Our Latest Stock Analysis on ANIX

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

Featured Articles

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.